Clene Inc (NAS:CLNN)
$ 0.3865 -0.0005 (-0.13%) Market Cap: 49.64 Mil Enterprise Value: 46.80 Mil PE Ratio: 0 PB Ratio: 3.72 GF Score: 38/100

Clene Inc. Presentation of RESCUE-ALS Topline Clinical Trial Results Transcript

Nov 02, 2021 / 12:00PM GMT
Release Date Price: $4.8 (-12.73%)
Operator

Presentation of RESCUE-ALS Topline Clinical Trial Results
Nov 02, 2021 / 12:00PM GMT

=====================
Corporate Participants
=====================
* John Woolford
Westwicke - Managing Director
* Rob Etherington
Clene, Inc. - Chairman and CEO
* Steve Vucic
University of Sydney - Northcott Chair of Neurology
* Robert Glanzman
Clene, Inc. - CMO
* Matthew Kiernan
University of Sydney - Bushell Chair of Neurology

=====================
Conference Call Participants
=====================
* Charles Duncan
Cantor Fitzgerald - Analyst
* Leland Gershell
Oppenheimer - Analyst
* Elemer Piros
Roth Capital Partners - Analyst
* Naz Rahman
Maxim Group - Analyst
* Bruce Jackson
The Benchmark Company - Analyst

=====================

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot